NASDAQ:DSGN Design Therapeutics (DSGN) Stock Price, News & Analysis → Man Who Predicted 2008: “This Will be Worse.” (From Altimetry) (Ad) Free DSGN Stock Alerts $3.66 -0.23 (-5.91%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$3.64▼$3.9750-Day Range$2.27▼$4.0352-Week Range$1.94▼$8.47Volume161,661 shsAverage Volume263,451 shsMarket Capitalization$206.75 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Design Therapeutics alerts: Email Address Design Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside50.3% Upside$5.50 Price TargetShort InterestBearish6.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$99,750 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.25) to ($1.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.34 out of 5 starsMedical Sector720th out of 910 stocksPharmaceutical Preparations Industry334th out of 426 stocks 3.0 Analyst's Opinion Consensus RatingDesign Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageDesign Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.75% of the float of Design Therapeutics has been sold short.Short Interest Ratio / Days to CoverDesign Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Design Therapeutics has recently increased by 4.21%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDesign Therapeutics does not currently pay a dividend.Dividend GrowthDesign Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DSGN. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 2 people have searched for DSGN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Design Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Design Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,750.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders25.70% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Design Therapeutics are expected to decrease in the coming year, from ($1.25) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Design Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Design Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDesign Therapeutics has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Design Therapeutics Stock (NASDAQ:DSGN)Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Read More DSGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSGN Stock News HeadlinesMarch 26, 2024 | insidertrades.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Director John P. Schmid Purchases 9,156 SharesMarch 26, 2024 | insidertrades.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Director Purchases $66,605.66 in StockApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 14, 2024 | americanbankingnews.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Rating of "Hold" from AnalystsMarch 27, 2024 | finance.yahoo.comIndependent Director of Design Therapeutics Picks Up 88% More StockMarch 26, 2024 | msn.comDesign Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingMarch 21, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)March 21, 2024 | markets.businessinsider.comHold Rating Maintained for Design Therapeutics Amid Drug Reformulation and Program UpdatesApril 23, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 20, 2024 | stockhouse.comDesign Therapeutics Outlines Progress Across GeneTAC(TM) Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 19, 2024 | investorplace.comDSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023March 19, 2024 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline ProgressMarch 19, 2024 | globenewswire.comDesign Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | investing.comDesign Therapeutics Inc (DSGN)March 18, 2024 | benzinga.comEarnings Preview For Design TherapeuticsMarch 15, 2024 | finance.yahoo.comDSGN Jul 2024 2.500 putMarch 15, 2024 | finance.yahoo.comDSGN Apr 2024 7.500 putMarch 12, 2024 | globenewswire.comDesign Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateFebruary 9, 2024 | benzinga.comSR ONE CAPITAL PARTNERS I, LP's Net WorthDecember 18, 2023 | finance.yahoo.comDesign Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should KnowDecember 7, 2023 | morningstar.comDesign Therapeutics Inc DSGNNovember 25, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy Design Therapeutics StockNovember 16, 2023 | markets.businessinsider.comHold Rating on Design Therapeutics Amid Mixed Efficacy Data, Strategic Realignment and Financial UncertaintiesNovember 14, 2023 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic UpdateNovember 13, 2023 | finance.yahoo.comDesign Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024September 8, 2023 | fool.comDesign Therapeutics (NASDAQ: DSGN)September 7, 2023 | benzinga.comDirector At This Health Care Company Buys $14.00M of StockSee More Headlines Receive DSGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today4/23/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DSGN CUSIPN/A CIK1807120 Webwww.designtx.com Phone858-293-4900FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+42.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-22.82% Return on Assets-21.82% Debt Debt-to-Equity RatioN/A Current Ratio29.58 Quick Ratio29.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.96 per share Price / Book0.78Miscellaneous Outstanding Shares56,490,000Free Float41,975,000Market Cap$218.62 million OptionableOptionable Beta1.82 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Pratik Shah Ph.D. (Age 54)Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Comp: $638.46kDr. Sean Jeffries Ph.D. (Age 44)Chief Operating Officer Comp: $572.21kDr. Aseem Z. Ansari Ph.D.Co-Founder & Scientific AdvisorMs. Julie D. Burgess CPAChief Accounting OfficerDr. Jae B. Kim FACC (Age 54)M.D., Chief Medical Officer Ms. Dawn GiangiulioControllerMore ExecutivesKey CompetitorsGeneration BioNASDAQ:GBIOZevra TherapeuticsNASDAQ:ZVRAGalectin TherapeuticsNASDAQ:GALTSilverback TherapeuticsNASDAQ:SBTXAbeona TherapeuticsNASDAQ:ABEOView All CompetitorsInsiders & InstitutionsJohn P SchmidBought 17,809 shares on 3/25/2024Total: $66,605.66 ($3.74/share)John P SchmidBought 9,156 shares on 3/22/2024Total: $33,144.72 ($3.62/share)Public Employees Retirement System of OhioBought 26,338 shares on 2/16/2024Ownership: 0.047%Pale Fire Capital SEBought 10,500 shares on 2/14/2024Ownership: 0.019%Tower Research Capital LLC TRC Bought 4,983 shares on 2/13/2024Ownership: 0.038%View All Insider TransactionsView All Institutional Transactions DSGN Stock Analysis - Frequently Asked Questions Should I buy or sell Design Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares. View DSGN analyst ratings or view top-rated stocks. What is Design Therapeutics' stock price target for 2024? 7 analysts have issued twelve-month price objectives for Design Therapeutics' stock. Their DSGN share price targets range from $4.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 50.3% from the stock's current price. View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts. How have DSGN shares performed in 2024? Design Therapeutics' stock was trading at $2.65 at the beginning of 2024. Since then, DSGN stock has increased by 38.1% and is now trading at $3.66. View the best growth stocks for 2024 here. When is Design Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our DSGN earnings forecast. How were Design Therapeutics' earnings last quarter? Design Therapeutics, Inc. (NASDAQ:DSGN) released its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.11. When did Design Therapeutics IPO? Design Therapeutics (DSGN) raised $228 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 12,000,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. How do I buy shares of Design Therapeutics? Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DSGN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
